Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address the Paradox of Choice

Download All
Hear from experts how the latest data from ASCO 2021 inform therapeutic strategies for patients with R/R MM and how to evaluate novel combination therapeutic regimens. Review their insights in clinical commentaries, slides, a podcast, and an on-demand webcast from a live CCO webinar.
Paul G. Richardson, MD
Program Director
person default
Nina Shah, MD
Peter M. Voorhees, MD

Downloadable Slidesets

Download this slideset based on the content from a live-stream CCO series from Paul G. Richardson on treatment options for patients with relapsed/refractory multiple myeloma who have relapsed after first-line therapy.

Paul G. Richardson, MD
Program Director
Released: June 23, 2021

Download this slideset based on the content from a live-stream CCO series from Peter M. Voorhees, MD on treatment options for patients with relapsed/refractory multiple myeloma who have relapsed after multiple lines of therapy.

Peter M. Voorhees, MD Released: June 24, 2021

Download this slideset based on the content from a live-stream CCO series from Nina Shah, MD on novel therapies under investigation for patients with relapsed/refractory multiple myeloma, including CAR T-cell therapies, bispecific antibodies, antibody drug conjugates, and CELMoDs.

person default Nina Shah, MD Released: June 24, 2021

Gain key clinical insights fast, with this short summary slideset from CCO on key considerations for optimal treatment selection for patients with relapsed/refractory myeloma.

Paul G. Richardson, MD
Program Director
person default Nina Shah, MD Peter M. Voorhees, MD
Released: June 25, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm
Oncopeptides
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue